Lead Sponsor

Hoffmann-La Roche

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adult patient (age \>/= 18 years)
•Presenting with WHO grade 1-3, CD20-positive follicular non-Hodgkin's lymphoma, histologically confirmed at initial diagnosis
•In relapse (or refractory) after at least one line of treatment, regardless of the nature of previous treatments (chemotherapy and/or immunotherapy and/or radioimmunoconjugate therapy and/or radiation+chemotherapy) and for whom a decision was made to give salvage therapy
•Having received oral and written information about the study and having raised no objections to electronic capture and processing of his/her personal data

•Patient participating in a clinical trial evaluating a new, non-commercialized cancer treatment at the time of inclusion
•Follicular lymphoma presenting with a transformation to diffuse large cell non-Hodgkin's lymphoma
•First line treatment with radiotherapy alone
•Initial abstention from treatment (decision to not treat the progression at the time of inclusion in the OLYMPE study)

Related studies

NCT06549595 · Untreated Follicular Lymphoma

NCT03190928 · Follicular Lymphoma

NCT06191744 · Follicular Lymphoma (FL)

NCT06852638 · Renal Cancer, Renal Clear Cell Carcinoma, and more

NCT05672251 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, and more

Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)